CoLucid Pharmaceuticals Announces Election of Mark Corrigan, M.D., to Board of Directors
October 27, 2015 08:00 ET
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., Oct. 27, 2015 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate,...
CoLucid Pharmaceuticals Announces Initiation of Phase 3 Long-Term, Open-Label Trial of Lasmiditan in Migraine
October 08, 2015 08:00 ET
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., Oct. 8, 2015 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate,...
CoLucid Pharmaceuticals to Present at Two Investor Conferences in September
September 03, 2015 08:00 ET
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., Sept. 3, 2015 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) today announced that Thomas P. Mathers, Chief Executive Officer, will provide a corporate overview at...
CoLucid Pharmaceuticals Announces Second Quarter 2015 Results and Corporate Highlights
August 12, 2015 16:01 ET
|
CoLucid Pharmaceuticals, Inc
Enrolled the first patient in the SAMURAI trial, the first of two phase 3 pivotal clinical trials investigating lasmiditan for the acute treatment of migraine headaches
Priced its initial...
CoLucid Pharmaceuticals Announces Appointment of Marvin L. White to Board of Directors
July 13, 2015 08:00 ET
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., July 13, 2015 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate,...
CoLucid Pharmaceuticals Announces Pricing of Initial Public Offering
May 06, 2015 09:00 ET
|
CoLucid Pharmaceuticals, Inc
BURLINGTON, Mass., May 6, 2015 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. ("CoLucid") (Nasdaq:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product...
CoLucid Pharmaceuticals Announces Initiation of First Phase 3 Pivotal Trial of Lasmiditan in Migraine
April 28, 2015 08:00 ET
|
CoLucid Pharmaceuticals, Inc
First Patient Randomized in SAMURAI STUDY
Trial Being Conducted Under Special Protocol Assessment Agreement with FDA
BURLINGTON, Mass., April 28, 2015 (GLOBE NEWSWIRE) -- CoLucid...